1. 認識乳癌及診斷. 乳癌防治基金會.
http://www.breastcf.org.tw/index.php/knowledge-base/knowing-breast-cancer-and-diagnostic. Accessed April 20th, 2018.
2. 中華民國 104 年癌症登記報告. 衛生福利部國民健康署.
https://www.hpa.gov.tw/Pages/Detail.aspx?nodeid=269&pid=8084. Accessed
April 20th, 2018.3. Cardoso F, Costa A, Senkus E, et al. 3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3). Ann Oncol 2017; 28(1):
16-33.
4. Cardoso F, Costa A, Norton L, et al. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)†. Ann Oncol 2014; 25(10):
1871-1888.
5. Hortobagyi GN, Stemmer SM, Burris HA, et al. Ribociclib as first-line
therapy for HR-positive, advanced breast cancer. N Engl J Med 2016; 375(18):
1738-1748.
6. NCCN Guidelines Version 1.2018, Breast Cancer.
https://www.nccn.org/professionals/physician_gls/default.aspx#site. Published
2018. Accessed, April 20, 2018.7. KISQALI® (ribociclib) tablets - Prescribing information. FDA.
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209092s000lbl.pd f. Published 2017. Accessed April 20, 2018.
8. Rugo HS, Rumble RB, Macrae E, et al. Endocrine Therapy for Hormone Receptor-Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline. J Clin Oncol 2016; 34(25): 3069-3103.
9. ATC/DDD Index. WHO Collaborating Centre for Drug Statistics Methodology.
https://www.whocc.no/atc_ddd_index/. Published 2018. Accessed April 20,
2018.10. 西藥、醫療器材、含藥化粧品許可證查詢. 衛生福利部食品藥物管理署.
http://www.fda.gov.tw/MLMS/H0001.aspx. Published 2018. Accessed Dec.
21th, April 20, 2018.
11. 藥材網路查詢. 衛生福利部中央健康保險署.
http://www.nhi.gov.tw/query/query1.aspx?menu=21&menu_id=713&webdata _id=3510&WD_ID=851. Published 2018. Accessed April 20, 2018.
12. 全民健康保險藥物給付項目及支付標準. 衛生福利部中央健康保險署.
http://www.nhi.gov.tw/webdata/webdata.aspx?menu=21&menu_id=713&web
107CDR03019_Kisqali
data_id=2919. Published 2018. Accessed April 20, 2018.
13. Ribociclib (Kisqali) Metastatic Breast Cancer – Final Clinical Guidance Report. CADTH.
https://cadth.ca/sites/default/files/pcodr/pcodr_ribociclib_kisqali_mbc_fn_cgr.
pdf. Published April 18, 2018. Accessed April 20, 2018.
14. Ribociclib (Kisqali) Metastatic Breast Cancer – pERC Final Recommendation.
CADTH.
https://cadth.ca/sites/default/files/pcodr/pcodr_ribociclib_kisqali_mbc_fn_rec.
pdf. Published April 18, 2018. Accessed April 20, 2018.
15. Hortobagyi GN, Stemmer SM, Burris HA, et al. Updated results from
MONALEESA-2, a phase 3 trial of first-line ribociclib + letrozole in hormone receptor-positive (HR+), HER2-negative (HER2-), advanced breast cancer (ABC). J Clin Oncol 2017; 35(15).
16. Verma S, O'Shaughnessy J, Burris HA, et al. Health-related quality of life (HRQoL) of postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) treated with ribociclib + letrozole: Results from
MONALEESA-2. J Clin Oncol 2017; 35(15_suppl): 1020-1020.
17. Pharmaceutical Benefits Scheme (PBS) - Ribociclib: Tablet 200 mg; Kisqali® . Australian Government Department of Health.
http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/psd/2017-11/ribociclib-psd-november-2017. Published Novermber, 2017. Accessed
April 20, 2018.18. Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer.
NICE.
https://www.nice.org.uk/guidance/ta496/chapter/3-Committee-discussion.
Published Decermber 20, 2017. Accessed April 20, 2018.
19. ribociclib (Kisqali). Scottish Medicine Consortium.
https://www.scottishmedicines.org.uk/medicines-advice/ribociclib-kisqali-fulls ubmission-129518/. Published March 12, 2018. Accessed April 20, 2018.
20. Janni W, Alba E, Bachelot T, et al. First-line ribociclib plus letrozole in postmenopausal women with HR+ , HER2− advanced breast cancer: Tumor response and pain reduction in the phase 3 MONALEESA-2 trial. Breast Cancer Res Treat 2018; ((Janni W., [email protected]) University of Ulm, Helmholtzstraße 18, Ulm, Germany): 1-11.
21. Verma S, O’Shaughnessy J, Burris HA, et al. Health-related quality of life of postmenopausal women with hormone receptor-positive, human epidermal
growth factor receptor 2-negative advanced breast cancer treated with
ribociclib + letrozole: results from MONALEESA-2. Breast Cancer Res Treat 2018: 1-11.
22. O’Shaughnessy J, Petrakova K, Sonke GS, et al. Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2− advanced breast cancer in the randomized MONALEESA-2 trial. Breast Cancer Res Treat 2018; 168(1): 127-134.
23. Janni W, Alba Conejo E, Bachelot T, et al. Duration of response and tumor shrinkage with first-line ribociclib 1 letrozole in postmenopausal women with HR1, HER2- ABC. Ann Oncol 2017; 28((Janni W.) Department of
Gynecology and Obstetrics, Ulm Medical University, Ulm, Germany): v78.
24. Pharmaceutical Benefits Scheme (PBS) - Ribociclib: Tablet 200 mg; Kisqali® . Australian Government Department of Health.
http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/psd/2017-07/ribociclib-psd-july-2017. Published July, 2017. Accessed April 20, 2018.
25. Suri, G., et al., PCN133 - Cost Effectiveness of Ribociclib Plus Letrozole Versus Palbociclib Plus Letrozole for The Treatment of Post-Menopausal Women with Hormone Receptor-Positive (HR+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Advanced or Metastatic Breast Cancer from A US Private Third-Party Payer Perspective. Value in Health, 2017. 20(9):
p. A436.
26. Hettle, R., et al., PCN119 - Cost-Effectiveness of Ribociclib Plus Letrozole Versus Palbociclib Plus Letrozole for Postmenopausal Women with Hormone Receptor-Positive (HR+), Human Epidermal Growth Factor Receptor
2-Negative (HER2–) Advanced/Metastatic Breast Cancer from A UK National Health Service Perspective. Value in Health, 2017. 20(9): p. A433.
27. 105 年死因統計結果分析. 衛生福利部統計處.
www.mohw.gov.tw/dl-33686-f713f1fb-bd64-4c0d-a810-cefabef4cb2e.html.
Published 2017. Accessed May 4, 2018.
28. 105 年各類癌症健保前 10 大醫療支出統計. 衛生福利部中央健康保險署.
www.nhi.gov.tw/DL.aspx?sitessn=292&u=LzAwMS9VcGxvYWQvMjkyL3Jl bGZpbGUvMC8yMzg2MC8xMDXlubTlkITpoZ7nmYznl4flgaXkv53liY0xM OWkp%2bmGq%2beZguaUr%2bWHuue1seioiC0xMDYwOC5wZGY%3d&
n=MTA15bm05ZCE6aGe55mM55eH5YGl5L%2bd5YmNMTDlpKfphqvnm YLmlK%2flh7rntbHoqIgtMTA2MDgucGRm&ico%20=.pdf. Published 2017.
Accessed May 4, 2018.
29. Lang HC, Wu SL. Lifetime costs of the top five cancers in Taiwan. Eur J Health Econ, 2012. 13(3): p. 347-353.
107CDR03019_Kisqali
30. Liao, G.-S., et al., The prognostic value of lymph node status among breast cancer subtypes. The American Journal of Surgery, 2015. 209(4): p. 717-724.
31. Parise CA, Caggiano V. Breast Cancer Survival Defined by the ER/PR/HER2 Subtypes and a Surrogate Classification according to Tumor Grade and Immunohistochemical Biomarkers. J Cancer Epidemiol, 2014;2014; 469251.
doi: 10.1155/2014/469251.
附錄
附錄一 療效評估文獻回顧搜尋策略 Cochrane library
ID 搜尋 (日期：2018/4/26) 篇數
#1 MeSH descriptor: [Breast Neoplasms] explode all trees 10,685
#2 ribociclib:ti,ab,kw (Word variations have been searched) 64
#3 #1 AND #2 (in Trials, Technology Assessments and Cochrane Groups)
4
Selected 1
PubMed
ID 搜尋 (日期：2018/4/26) 篇數
#1 Kisqali[tiab] OR ribociclib[tiab] OR
"ribociclib"[Supplementary Concept]
128
#2 "Breast Neoplasms/drug therapy"[Mesh] 49,731
#3 #1 AND #2 AND (Clinical Trial, Phase III[ptyp] AND English[lang])
1
Selected 1
Embase
ID 搜尋 (日期：2018/4/26) 篇數
#1 'ribociclib'/exp 509
#2 'breast cancer'/exp 406,236
#3 #1 AND #2 314
#4 #1 AND #2 AND [randomized controlled trial]/lim AND [humans]/lim AND [english]/lim AND 'phase 3 clinical trial'/de
28
Selected 12
107CDR03019_Kisqali
附錄二、經濟評估文獻搜尋策略
資料庫 查詢日期 關鍵字 篇數 篩選後篇數
PubMed 2018.05.04 #1 breast cancer
#2 ribociclib
#3 (((cost-effectiveness analysis) OR
cost-utility analysis) OR cost-benefit
analysis) OR
cost-minimization analysis
#1 AND #2 AND #3
1 0
EMBASE 2018.05.04 #1 breast cancer
#2 ribociclib
#3 (((cost-effectiveness analysis) OR
cost-utility analysis) OR cost-benefit analysis) OR cost-minimization analysis
#1 AND #2 AND #3
3 2
Cochrane Library
2018.05.04 #1 breast cancer
#2 ribociclib
#3 (((cost-effectiveness analysis) OR
cost-utility analysis) OR cost-benefit analysis) OR cost-minimization analysis
#1 AND #2 AND #3
1 0
CRD 2018.05.04 #1 cost-effectiveness analysis AND ribociclib
#2 cost-utility analysis AND ribociclib
#3 cost-benefit analysis AND ribociclib
#4 cost-minimization analysis AND ribociclib
0 0
Airiti Library 2018.05.04 ribociclib 4 0